Himani Mongia, Fatima Mamnoon, Arunima Silsarma, Raman Mahajan, Alpa Dalal, Miriam Arago Galindo, Aparna Iyer, Pramila Singh, Homa Mansoor, Mrinalini Das, Mabel Morales, Hannah Spencer, Petros Isaakidis
BACKGROUND: World Health Organization suggests concurrent bedaquiline-delamanid (BDQ-DLM) as part of individualised regimens for eligible patients with pulmonary drug-resistant tuberculosis (DR-TB); however, data for patients with drug-resistant extrapulmonary tuberculosis (EPTB) is extremely limited. This study documents the treatment outcomes and adverse events associated with concurrent BDQ-DLM-based regimens in patients with drug-resistant EPTB at a Médecins Sans Frontières clinic in Mumbai, India...
May 2024: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases